HOME
SERVICE
PRODUCTS
New Products
CytokinesNew Immune CheckpointsNew GPCRsNew TAANew KinaseNew KinaseNew TLRNew ImmuneNew NKNew OtherNew
Hot Products
ADCC and ADCPHot Luciferase-labeled cell linesHot CLDNHot LILRHot WntHot TLRHot TNFHot testHot
INFORMATION
CONTACT US
ABOUT US
Search
CN
CN
HOME
SERVICE
PRODUCTS
INFORMATION
CONTACT US
ABOUT US
OUR PRODUCT
Lentivirus Services
Stable Cell Line Development
In vitro pharmacology
ADCC and ADCP assay
Service
Here is the new product introduction information, please provide the information.
Cytokines
Immune Checkpoints
GPCRs
TAA
Kinase
Kinase
TLR
Immune
NK
Other
New Products
Here is the new product introduction information, please provide the information.
ADCC and ADCP
Luciferase-labeled cell lines
CLDN
LILR
Wnt
TLR
TNF
test
Hot Products
Here is the new product introduction information, please provide the information.
ABOUT US
Jiman Biotechnology (Shanghai) Co., Ltd. is a high-tech enterprise specializing in the research and development of cutting-edge biotechnology. Company spirit of "focus, innovation, integrity and harmony" business philosophy, dedicated to provide biological technology services and related products, many companies and research institutions at home and abroad to provide a virus packaging, steady carrier strains build, build, protein expression, genetic programming (CAS9), gene function and drug screening and other technical services, and related products. The core team of the company has been engaged in research and development for many years in domestic and foreign famous universities and international first-class pharmaceutical companies.
MORE +
INFORMATION
Research and development status of PD-(L)1/TGF-β dual antibody
2022-09-05
On May 12, 2021, Hergrui PD-L1/TGFβ dual antibody SHR-1701 was declared as another clinical project. Up to now, SHR-1701 has entered clinical projects in 14, including 11 in China.
Research and development status of PD-(L)1/TGF-β dual antibody
2022-09-05
On May 12, 2021, Hergrui PD-L1/TGFβ dual antibody SHR-1701 was declared as another clinical project. Up to now, SHR-1701 has entered clinical projects in 14, including 11 in China.
Research and development status of PD-(L)1/TGF-β dual antibody
2022-09-05
On May 12, 2021, Hergrui PD-L1/TGFβ dual antibody SHR-1701 was declared as another clinical project. Up to now, SHR-1701 has entered clinical projects in 14, including 11 in China.
COOPERATION
恒瑞
恒瑞
恒瑞
恒瑞
恒瑞
恒瑞
恒瑞
恒瑞
恒瑞
恒瑞
石药
1
1
1
1
1
1
1
OUR PRODUCT
Service
Here is the new product introduction information, please provide the information
New Products
Here is the new product introduction information, please provide the information.
Hot Products
Here is the new product introduction information, please provide the information.
ABOUT US
Jiman Biotechnology (Shanghai) Co., Ltd. is a high-tech enterprise specializing in the research and development of cutting-edge biotechnology. Company spirit of "focus, innovation, integrity and harmony" business philosophy, dedicated to provide biological technology services and related products, many companies and research institutions at home and abroad to provide a virus packaging, steady carrier strains build, build, protein expression, genetic programming (CAS9), gene function and drug screening and other technical services, and related products. The core team of the company has been engaged in research and development for many years in domestic and foreign famous universities and international first-class pharmaceutical companies. MORE +
INFORMATION
Research and development status of PD-(L)1/TGF-β dual antibody
2022-09-05
On May 12, 2021, Hergrui PD-L1/TGFβ dual antibody SHR-1701 was declared as another clinical project. Up to now, SHR-1701 has entered clinical projects in 14, including 11 in China.
Research and development status of PD-(L)1/TGF-β dual antibody
2022-09-05
On May 12, 2021, Hergrui PD-L1/TGFβ dual antibody SHR-1701 was declared as another clinical project. Up to now, SHR-1701 has entered clinical projects in 14, including 11 in China.
Research and development status of PD-(L)1/TGF-β dual antibody
2022-09-05
On May 12, 2021, Hergrui PD-L1/TGFβ dual antibody SHR-1701 was declared as another clinical project. Up to now, SHR-1701 has entered clinical projects in 14, including 11 in China.
MORE +
COOPERATION
恒瑞
恒瑞
恒瑞
恒瑞
恒瑞
恒瑞
恒瑞
恒瑞
恒瑞
恒瑞
石药
1
1
1
1
1
1
1
CONTACT
Tel: 400-627-9288
Email: service@genomeditech.com
Address: 5th Floor, Building 1, Lane 299, Kangwei Road, Pudong New Area, Shanghai
Copyright © 2022 Genomeditech(Shanghai) Co.,LTD
Privacy policy
CONTACT
Tel: 400-627-9288
Email: service@genomeditech.com
Address: 5th Floor, Building 1, Lane 299, Kangwei Road, Pudong New Area, Shanghai
Copyright © 2022 Genomeditech(Shanghai) Co.,LTD
Privacy policy
HOME
PRODUCT
CONTACT US
NEWS